CN1503680A - 用于金属放射性药物的抗坏血酸类似物 - Google Patents

用于金属放射性药物的抗坏血酸类似物 Download PDF

Info

Publication number
CN1503680A
CN1503680A CNA028087186A CN02808718A CN1503680A CN 1503680 A CN1503680 A CN 1503680A CN A028087186 A CNA028087186 A CN A028087186A CN 02808718 A CN02808718 A CN 02808718A CN 1503680 A CN1503680 A CN 1503680A
Authority
CN
China
Prior art keywords
pharmaceutical composition
replaces
radiopharmaceutical
biomolecule
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028087186A
Other languages
English (en)
Chinese (zh)
Inventor
S
S·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of CN1503680A publication Critical patent/CN1503680A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CNA028087186A 2001-02-26 2002-02-22 用于金属放射性药物的抗坏血酸类似物 Pending CN1503680A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27138901P 2001-02-26 2001-02-26
US60/271,389 2001-02-26

Publications (1)

Publication Number Publication Date
CN1503680A true CN1503680A (zh) 2004-06-09

Family

ID=23035343

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028087186A Pending CN1503680A (zh) 2001-02-26 2002-02-22 用于金属放射性药物的抗坏血酸类似物

Country Status (12)

Country Link
US (1) US6713042B2 (enExample)
EP (1) EP1365813A4 (enExample)
JP (1) JP2004529884A (enExample)
CN (1) CN1503680A (enExample)
AU (1) AU2002253999A1 (enExample)
BR (1) BR0207315A (enExample)
CA (1) CA2438204A1 (enExample)
CZ (1) CZ20032597A3 (enExample)
HU (1) HUP0304083A2 (enExample)
IL (1) IL157359A0 (enExample)
MX (1) MXPA03007595A (enExample)
WO (1) WO2002067859A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI604853B (zh) * 2016-05-03 2017-11-11 行政院原子能委員會核能研究所 放射免疫複合體、診療劑及套組

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
US20050089471A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20050089470A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
BRPI0711818A2 (pt) * 2006-05-19 2011-12-13 Nihon Medi-Physics Co., Ltd. novo composto com afinidade pela amilóide
CN101501033B (zh) * 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
WO2007148088A2 (en) * 2006-06-21 2007-12-27 Ge Healthcare Limited Radiopharmaceutical products
WO2008056481A1 (en) * 2006-11-09 2008-05-15 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
US20090252680A1 (en) * 2006-11-17 2009-10-08 Nihon- Medi-Physics Co., Ltd Novel compound with affinity for amyloid
CA2670436A1 (en) * 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
US8790620B2 (en) * 2006-12-21 2014-07-29 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
CN101636183B (zh) 2007-02-13 2014-03-19 日本医事物理股份有限公司 放射性诊断显像剂的制备方法
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
AU2008314870A1 (en) * 2007-10-24 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
AU2008319986A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
EP2218463A1 (en) * 2007-10-30 2010-08-18 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
US20100284912A1 (en) * 2007-12-04 2010-11-11 Bracco Diagnostics Inc. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
US20110206608A1 (en) * 2008-09-05 2011-08-25 Jianqing Chen Pharmaceutical Composition Of A Radioiodinated Benzamide Derivative And Methods Of Making Same
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
JP5662416B2 (ja) * 2009-04-15 2015-01-28 ランセウス メディカル イメージング， インコーポレイテッド アスコルビン酸による放射性医薬組成物の安定化
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
WO2013093099A1 (en) * 2011-12-22 2013-06-27 Piramal Imaging Sa Stabilization of peptidic radiopharmaceuticals using uric acid or derivatives thereof
US9550704B2 (en) 2012-05-24 2017-01-24 Futurechem Co., Ltd. Method for synthesizing radiopharmaceuticals using a cartridge
US20140147381A1 (en) * 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
AU2014216515A1 (en) * 2013-02-15 2015-10-08 Thomas Jefferson University Kit for tumor imaging
WO2016085127A2 (ko) * 2014-11-27 2016-06-02 (주)셀트리온 펩타이드가 결합된 안정한 아스코르빈산 유도체, 그의 제조방법 및 그를 포함하는 화장료 조성물
CN107167540B (zh) * 2017-07-08 2019-07-30 万舒（北京）医药科技有限公司 测定人尿液生物样品中的DTPA-Zn的方法
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167378B (enExample) * 1972-05-08 1975-09-27
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
EP0422712B1 (en) * 1989-10-09 1994-03-09 Unilever N.V. Process for manufacture of edible spreads and apparatus for the performance of said process
DE69231469T2 (de) * 1991-08-29 2001-01-25 Mallinckrodt Medical, Inc. Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
WO2002004030A2 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI604853B (zh) * 2016-05-03 2017-11-11 行政院原子能委員會核能研究所 放射免疫複合體、診療劑及套組

Also Published As

Publication number Publication date
WO2002067859A3 (en) 2002-11-28
AU2002253999A1 (en) 2002-09-12
EP1365813A2 (en) 2003-12-03
MXPA03007595A (es) 2003-12-04
CZ20032597A3 (cs) 2004-12-15
CA2438204A1 (en) 2002-09-06
WO2002067859A2 (en) 2002-09-06
EP1365813A4 (en) 2006-03-22
BR0207315A (pt) 2004-02-10
JP2004529884A (ja) 2004-09-30
HUP0304083A2 (hu) 2004-03-29
US20020122769A1 (en) 2002-09-05
US6713042B2 (en) 2004-03-30
IL157359A0 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
CN1503680A (zh) 用于金属放射性药物的抗坏血酸类似物
CN1093424C (zh) 含单胺、联氨、硫羟基的金属螯合剂
US20020122768A1 (en) Stable radiopharmaceutical compositions and methods for preparation thereof
CN1087631C (zh) 用于诊断和治疗的放射性标记肽
AU2014396468B2 (en) Modified cyclopentapeptides and uses thereof
EP2785712B1 (en) Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
CN1254276C (zh) 作为诊断剂中靶组分的基质金属蛋白酶抑制剂
KR20240019301A (ko) 트리스링커-접합된 이량체 표지 전구체 및 이로부터 유도되는 방사성 추적자
TWI875842B (zh) 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體
KR20210110834A (ko) 이중 방식의 18f-표지된 테라노스틱 화합물 및 그 용도
CN1622830A (zh) 肽基化合物
CN1527727A (zh) 改进的螯合剂共轭物
SI9620076A (sl) Stabilni reagenti za pripravo radiofarmacevtikov
CN1155248A (zh) 生长激素抑制素结合肽-金属络合物
CN1154072A (zh) 用于成象的锝-99m标记的肽
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
KR20220063214A (ko) Grpr 길항제의 방사성표지 방법 및 이의 키트
CA3171753A1 (en) Stable formulations for radionuclide complexes
JP2014505021A (ja) アポトーシス用ｐｅｔイメージング剤
CN1968963A (zh) 基于肽的化合物
Davis et al. Fully automated peptide radiolabeling from [18 F] fluoride
EP4590345A2 (en) High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
JP2009500410A (ja) イメージング剤としてのヒドラジドコンジュゲート
CA3217801A1 (en) Chelators for radiometals and methods of making and using same
Klenner et al. Labeled rhenium complexes: radiofluorination, α-MSH cyclization, and deuterium substitutions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication